Please login to the form below

Not currently logged in
Email:
Password:

Pfizer finalises deals for Ferrosan Consumer Health and Excaliard

US pharma company completes purchase of skincare specialist Excaliard Pharmaceuticals and dietary and lifestyle firm Ferrosan

Pfizer has completed two acquisitions that develop its interests in the skincare and consumer products markets.

The US pharma company has finalised its deals to buy Ferrosan Consumer Health from private equity firm Altor as well as Excaliard Pharmaceuticals, a US biopharma company focused on developing novel drugs for the treatment of skin fibrosis.

Pfizer's acquisition of Excaliard will see the pharma company gain full rights to the company's investigational treatments, including its phase II candidate EXC 001.

The drug is being developed to limit the process of skin fibrosis by inhibiting the expression of the body's connective tissue growth factor – a cause of skin scarring following surgery or injury. This is a therapy area for which there is currently no FDA approved medication.

According to Pfizer, phase II trials have been positive in reducing skin scarring, with the company keen to develop the treatment further.

Jose-Carlos Gutierrez-Ramos, senior vice president, Biotherapeutics, Worldwide Research and Development at Pfizer, said: “It is imperative at Pfizer that we continue to develop new and innovative treatments to address unmet medical needs.

“Acquiring Excaliard allows us to continue the development of its lead compound EXC 001 to potentially fill a gap and bring a novel new treatment to patients.”

The Ferrosan deal, originally announced in February, will see Pfizer enhance its presence in the Nordic region, as well as Russia and Ukraine, where Ferrosan is well-established.

Its products include the Centrum multivitamins brand and Caltrate, a calcium supplement.

Paul Sturman, president of Pfizer Consumer Healthcare, said Ferrosan was a “strong fit” for Pfizer's consumer business, which is looking to expand in more emerging markets.

Financial terms of both deals were undisclosed, however, Excaliard's shareholders, which include Isis Pharmaceuticals, will received both an upfront payment as well as certain milestone rewards if certain development and commercialisation objectives are met.

5th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics